ENvue Medical Inc. (FEED) - Total Liabilities
Based on the latest financial reports, ENvue Medical Inc. (FEED) has total liabilities worth $7.86 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ENvue Medical Inc. - Total Liabilities Trend (2011–2025)
This chart illustrates how ENvue Medical Inc.'s total liabilities have evolved over time, based on quarterly financial data. See operational self-sufficiency of ENvue Medical Inc. to measure how many days the company can operate on defensive assets alone.
ENvue Medical Inc. Competitors by Total Liabilities
The table below lists competitors of ENvue Medical Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indus Gas Ltd
F:59Q
|
Germany | €1.06 Billion |
|
Tissue Repair Ltd
AU:TRP
|
Australia | AU$607.50K |
|
APC Minerals Ltd
AU:APC
|
Australia | AU$422.25K |
|
NOROO Paint & Coatings Co Ltd
KO:090355
|
Korea | ₩280.30 Billion |
|
City Office
NYSE:CIO
|
USA | $456.78 Million |
|
Telo Genomics Corp
V:TELO
|
Canada | CA$633.60K |
Liability Composition Analysis (2011–2025)
This chart breaks down ENvue Medical Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ENvue Medical Inc. asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ENvue Medical Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ENvue Medical Inc. (2011–2025)
The table below shows the annual total liabilities of ENvue Medical Inc. from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.63 Million | +154.06% |
| 2024-12-31 | $3.00 Million | +11.76% |
| 2023-12-31 | $2.69 Million | +1.51% |
| 2022-12-31 | $2.65 Million | +14.60% |
| 2021-12-31 | $2.31 Million | -60.43% |
| 2020-12-31 | $5.83 Million | +748.11% |
| 2019-12-31 | $688.00K | -38.41% |
| 2018-12-31 | $1.12 Million | -9.26% |
| 2017-12-31 | $1.23 Million | -58.87% |
| 2016-12-31 | $2.99 Million | +36.54% |
| 2015-12-31 | $2.19 Million | -65.42% |
| 2014-12-31 | $6.34 Million | +58.95% |
| 2013-12-31 | $3.99 Million | +82.85% |
| 2012-12-31 | $2.18 Million | +30.60% |
| 2011-12-31 | $1.67 Million | -- |
About ENvue Medical Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, incre… Read more